Key Highlights
• Up to $8.8 Million Deal: Cadrenal Therapeutics (NASDAQ: CVKD) signed a private placement of up to $8.8 million with a single healthcare-focused institutional investor.
• $3 Million Upfront: The company receives $3 million upfront through 960,000 shares or pre-funded warrants, plus Series C-1 and C-2 warrants.
• H.C. Wainwright Placement Agent: H.C. Wainwright & Co. acted as exclusive placement agent, with warrants potentially adding $5.8 million if exercised for cash.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) took a smaller and more structured route to raising capital. The company entered a definitive agreement with a single healthcare-focused institutional investor for a private placement of up to $8.8 million, priced at-the-market under Nasdaq rules.
The deal delivers $3 million upfront through the sale of 960,000 shares of common stock, or pre-funded warrants, together with accompanying Series C-1 and C-2 warrants. The combined purchase price is $3.125 per share and accompanying warrant.
If the warrants are fully exercised for cash, they could generate an additional $5.8 million in gross proceeds, bringing the total potential raise to $8.8 million. H.C. Wainwright & Co. acted as exclusive placement agent for the offering.
The structure is typical for micro-cap biotech. A modest upfront infusion addresses immediate funding needs, while the warrant coverage offers additional upside if the shares appreciate and the warrants are exercised. This approach avoids committing to a large equity block all at once and ties part of the proceeds to future share performance.
Pricing the placement at-the-market under Nasdaq rules is a common feature of these deals, keeping the transaction aligned with prevailing market levels. Using a single institutional investor can also streamline the process compared with a broad public offering.
For Cadrenal Therapeutics (NASDAQ: CVKD), the raise provides near-term operating flexibility. The key considerations for investors include how quickly the warrants might be exercised, the dilution associated with the full $8.8 million if realized, and how the company deploys the capital across its clinical priorities. Whether the warrants convert to cash depends largely on future share performance.






Please wait processing your request...